北京中新药业

Beijing Neptunus Zhongxin Pharmaceutical Co., Ltd. (formerly Beijing Zhongxin Pharmaceutical Co., Ltd.) is a comprehensive pharmaceutical company founded in 1990 and based in Miyun, Beijing. Originally established as the pilot pharmaceutical factory of the China National Center for Biotechnology Development, the company was restructured and eventually acquired by Shenzhen Neptunus Interlong Bio-technique Co., Ltd. in 2021. The company holds 137 national drug approvals in China, covering therapeutic areas such as cardiovascular diseases, metabolic disorders, neuropsychiatric disorders, and anti-infectives. Its commercial product portfolio includes widely used generic drugs such as captopril, metformin, ibuprofen, diazepam, and oryzanol. Beijing Neptunus Zhongxin Pharmaceutical operates multiple GMP-certified production lines for tablets, capsules, granules, and powders.